ArticleScientific reports2025
Clinical value of D-dimer combined with transvaginal ultrasonography in the postmenopausal population with endometrial carcinoma.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To evaluate the diagnostic value of plasma D-dimer combined with transvaginal ultrasonography for endometrial carcinoma in postmenopausal women, addressing the increasing incidence in China. This retrospective study analyzed 129 postmenopausal women (July 2021-January 2023) undergoing hysteroscopy, including 61 with endometrial carcinoma (mean age 56.5 ± 6.8 years) and 68 with benign lesions (60.2 ± 7.7 years). We assessed D-dimer levels, ultrasonographic parameters (endometrial thickness, uterine cavity occupation, blood flow signals), and postmenopausal bleeding. Diagnostic performance was evaluated using ROC curves. Multivariate analysis identified three independent predictors: intracavitary blood flow (OR 60.44, 95% CI 8.25-442.98, p < 0.001), postmenopausal bleeding (OR 5.84, 95% CI 1.82-18.75, p = 0.003), and elevated D-dimer (OR 3.12, 95% CI 1.06-9.22, p = 0.04). The comprehensive model achieved superior diagnostic performance (AUC = 0.920, sensitivity = 88.5%, specificity = 85.3%) compared to any individual parameter. Plasma D-dimer combined with transvaginal ultrasonography and clinical symptoms provides an effective screening approach for postmenopausal endometrial carcinoma, serving as a valuable risk assessment strategy for identifying candidates requiring definitive histopathological examination.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.